Literature DB >> 17879904

Urolithiasis in HIV-positive patients treated with atazanavir.

Carine Couzigou1, Michel Daudon, Jean Luc Meynard, Françoise Borsa-Lebas, Denise Higueret, Lélia Escaut, David Zucman, Jean-Yves Liotier, Jean-Louis Quencez, Karine Asselah, Thierry May, Didier Neau, Daniel Vittecoq.   

Abstract

Among protease inhibitors, atazanavir has not been associated with urolithiasis in clinical studies. We describe 11 cases of atazanavir-associated urolithiasis in patients with human immunodeficiency virus (HIV) infection. Patients with low water intake, high urinary pH, and a prior history of urinary stones may have a higher risk of atazanavir-associated urine crystallization.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17879904     DOI： 10.1086/521930

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  27 in total

1.  Recurrent nephrolithiasis associated with atazanavir use.

Authors:  Lily C Wang; E Charles Osterberg; Scott G David; James S Rosoff
Journal:  BMJ Case Rep       Date:  2014-01-08

Review 2.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

3.  Renal stone composed of ritonavir.

Authors:  Anna M Zhao; Nancy R Angoff
Journal:  BMJ Case Rep       Date:  2019-07-01

Review 4.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  The nephrotoxic effects of HAART.

Authors:  Hassane Izzedine; Marianne Harris; Mark A Perazella
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

6.  Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient.

Authors:  Yoji Moriyama; Yuzuru Minamidate; Mitsuru Yasuda; Hidetoshi Ehara; Mina Kikuchi; Tomohiro Tsuchiya; Takashi Deguchi; Hisashi Tsurumi
Journal:  Urol Res       Date:  2008-07-17

Review 7.  Proteinuria in paediatric patients with human immunodeficiency virus infection.

Authors:  Vania Giacomet; Paola Erba; Francesca Di Nello; Sonia Coletto; Alessandra Viganò; Gianvincenzo Zuccotti
Journal:  World J Clin Cases       Date:  2013-04-16       Impact factor: 1.337

8.  Role of atazanavir in the treatment of HIV infection.

Authors:  Pablo Rivas; Judit Morello; Carolina Garrido; Sonia Rodríguez-Nóvoa; Vincent Soriano
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

9.  Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses.

Authors:  Bruno Bezerril Andrade; Katherine Huppler Hullsiek; David R Boulware; Adam Rupert; Martyn A French; Kiat Ruxrungtham; Marisa Luisa Montes; Huw Price; Pablo Barreiro; Jennifer Audsley; Alan Sher; Sharon R Lewin; Irini Sereti
Journal:  J Infect Dis       Date:  2013-01-18       Impact factor: 5.226

Review 10.  Nanoparticle delivery system, highly active antiretroviral therapy, and testicular morphology: The role of stereology.

Authors:  Edwin Coleridge S Naidu; Samuel Oluwaseun Olojede; Sodiq Kolawole Lawal; Carmen Olivia Rennie; Onyemaechi Okpara Azu
Journal:  Pharmacol Res Perspect       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.